The Technical Analyst
Graybug Vision, Inc. [GRAY]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Graybug Vision, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-10.80% $5.50
America/New_York / 20 mar 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 120.98 mill |
| EPS: | -20.63 |
| P/E: | -0.267 |
| Earnings Date: | Aug 09, 2023 |
| SharesOutstanding: | 22.00 mill |
| Avg Daily Volume: | 0.0053 mill |
| RATING 2023-05-17 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.267 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.05x |
| Company: PE -0.267 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.08 - 3.32 ( +/- 22.89%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-11 | Wilson Robert N | Buy | 506 | Common Stock |
| 2023-11-07 | Leheny A. Rachel | Buy | 2 000 | Common Stock |
| 2023-11-06 | Roberts Eric W | Buy | 2 400 | Common Stock |
| 2023-11-03 | Roberts Eric W | Buy | 11 249 | Common Stock |
| 2023-11-03 | Roberts Eric W | Buy | 3 700 | Common Stock |
| INSIDER POWER |
|---|
| 96.27 |
| Last 97 transactions |
| Buy: 3 103 303 | Sell: 60 672 |
Forecast:
01:40 - $4.03
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.50 (-10.80% ) |
| Volume | 0.0246 mill |
| Avg. Vol. | 0.0053 mill |
| % of Avg. Vol | 466.70 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GRAY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GRAY
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Last 10 Buy Signals
Latest Press Releases
2022-07-06 07:15:00 - Press Release
Graybug To Present At The 2022 Ois Retina Innovation Summit
Baltimore, july 06, 2022 (globe newswire) -- graybug vision, inc. (nasdaq: gray), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming ophthalmology innovation source (ois) retina innovation summit, to be held in new york city on july 13, 2022.
2022-05-19 07:30:00 - Press Release
Graybug To Present Clinical Development Plan Update For Gb-102 At The 2022 Clinical Trials At The Summit Meeting
Baltimore, may 19, 2022 (globe newswire) -- graybug vision, inc. (nasdaq: gray), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that parisa zamiri, md, phd, chief medical officer of graybug vision, will present an update on the clinical development plan for gb-102 in wet age-related macular degeneration, and will be part of a subsequent panel discussion at the upcoming clinical trials at the summit meeting, to be held in person at the hyatt regency lake tahoe in nevada, as well as virtually, on may 21, 2022.
2022-04-18 07:30:00 - Press Release
Graybug To Present At The 2022 Ascrs Annual Meeting
Baltimore, april 18, 2022 (globe newswire) -- graybug vision, inc. (nasdaq: gray), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming american society of cataract and refractive surgery (ascrs) annual meeting, to be held in washington, d.c. from april 22-26, 2022.
2022-02-03 07:30:00 - Press Release
Graybug To Participate In Three Upcoming Medical And Investor Conferences
Baltimore, feb. 03, 2022 (globe newswire) -- graybug vision, inc. (nasdaq: gray), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced its participation in three upcoming medical and investor conferences:
2021-09-30 16:05:00 - Press Release
Graybug Vision To Participate In The Annual Ophthalmology Innovation Summit (ois) Retina@asrs Conference
Baltimore, sept. 30, 2021 (globe newswire) -- graybug vision, inc. (nasdaq: gray), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that fred guerard, pharmd, chief executive officer of graybug vision, will participate in the following events at the ophthalmology innovation summit (ois) retina on thursday, october 7, 2021, in san antonio, texas. the ois retina conference is being held in conjunction with the american society of retina specialists (asrs) 39th annual scientific meeting. dr. guerard will be a speaker at the following events:
Latest News
2022-08-09 14:11:51 - PennyStocks
Penny Stocks To Watch: Why REVB, RVPH, BARK, and GRAY Stock Are Moving
Hot penny stocks to watch this week. The post Penny Stocks To Watch: Why REVB, RVPH, BARK, and GRAY Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-07-06 07:15:00 - GlobeNewsWire
Graybug to Present at the 2022 OIS Retina Innovation Summit
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming Ophthalmology Innovation Source (OIS) Retina Innovation Summit, to be held in New York City on July 13, 2022.
2022-06-29 13:55:15 - Zacks Investment Research
Graybug (GRAY) to Review Strategic Alternatives, Stock Up
Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.
2022-06-28 15:07:40 - InvestorPlace
Graybug Vision (GRAY) Stock Soars 35% on Strategic Review News
Today, investors in Graybug Vision and GRAY stock are cheering an announced strategic review, which could see a sale of the company. The post Graybug Vision (GRAY) Stock Soars 35% on Strategic Review News appeared first on InvestorPlace.
2022-06-28 12:30:25 - PennyStocks
Best Penny Stocks For July 2022? 5 To Watch Right Now
2022-05-19 07:30:00 - GlobeNewsWire
Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting
BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug Vision, will present an update on the clinical development plan for GB-102 in wet age-related macular degeneration, and will be part of a subsequent panel discussion at the upcoming Clinical Trials at the Summit Meeting, to be held in person at the Hyatt Regency Lake Tahoe in Nevada, as well as virtually, on May 21, 2022.
2022-04-18 07:30:00 - GlobeNewsWire
Graybug to Present at the 2022 ASCRS Annual Meeting
BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, to be held in Washington, D.C. from April 22-26, 2022.
2022-02-03 07:30:00 - GlobeNewsWire
Graybug to Participate in Three Upcoming Medical and Investor Conferences
BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced its participation in three upcoming medical and investor conferences:
2021-09-30 16:05:00 - GlobeNewsWire
Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference
BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in the following events at the Ophthalmology Innovation Summit (OIS) Retina on Thursday, October 7, 2021, in San Antonio, Texas. The OIS Retina conference is being held in conjunction with the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting. Dr. Guerard will be a speaker at the following events:
2021-09-28 07:30:00 - GlobeNewsWire
Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD
BALTIMORE, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD), Graybug's proprietary formulation of sunitinib malate injected twice-a-year intravitreally.